Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis

  • David R. Chow, MD, FRCS(C)
  • Video
  • Published 2023

See more